Bone mineral density and body composition and influencing factors in children with rheumatic diseases treated with corticosteroids.
In rheumatic diseases the use of corticosteroids (CS), immobility, or the disease itself, may cause osteoporosis and growth retardation. We evaluated bone mineral density (BMD) by dual energy X-ray absorptiometry (DXA), growth and physical activity in 27 children with rheumatic disease, all treated with high dose CS for at least one year, in a cross-sectional design. BMD SDS was significantly lower than zero: -1.02 for total body and -1.49 for lumbar spine measurement. SDS for fat mass was higher than zero. In multiple regression analysis the Child Health Assessment Questionnaire score significantly correlated with BMD of the lumbar spine. There was no significant correlation with cumulative dose or duration of CS treatment. Height SDS decreased during treatment to -1.57 (p <0.001 compared to 0). In conclusion, BMD and body composition in children with rheumatic disease treated with CS are influenced by physical activity, as well as corticosteroid treatment and type of rheumatic disease.
Mul
D
D
Department of Paediatrics, University Hospital Rotterdam and Sophia Children's Hospital, The Netherlands. mul@alkg.azr.nl
van Suijlekom-Smit
L W A
LW
ten Cate
R
R
Bekkering
W P
WP
de Muinck Keizer-Schrama
S M P F
SM
D015502:Absorptiometry, Photon; D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000009:adverse effects*; D001823:Body Composition; D015519:Bone Density; D002648:Child; D003430:Cross-Sectional Studies; D015444:Exercise; D005260:Female; D006801:Humans; D008297:Male; D012044:Regression Analysis; D012216:Rheumatic Diseases / Q000188:drug therapy* / Q000503:physiopathology; D011795:Surveys and Questionnaires
D000305:Adrenal Cortex Hormones